Silk Therapeutics Hires Eva Genel as Director of Research and Development, Skincare

MEDFORD, Mass., Sept. 19, 2017 /PRNewswire/ -- Silk Therapeutics Inc., a specialty biomaterials company, today announced the hire of Eva Genel as Director of Research and Development, Skincare. In this new role, Genel's key responsibilities include designing and assessing clean, skincare formulations, overseeing testing, while spearheading new innovation, and product development. Genel relocated from Paris, France and is now based in the company's Medford, MA, headquarters, reporting to Greg Altman, CEO of Silk Therapeutics.

"We are elated to have Eva join our team, leading R&D and innovation across our growing skincare portfolio," said Altman. "Eva's experience within the industry provides Silk Therapeutics an invaluable source of expertise to help us both strengthen our current portfolio, while helping to develop the next generation of liquid, silk-based skincare formulas. Lastly, her vast knowledge of European skincare regulations will also empower us to develop and test against a stricter set of standards, which already include those of the Environmental Working Group (EWG), providing customers clean product offerings with minimal ingredients."

Genel joins Silk Therapeutics with over 15 years of skincare and ingredient-testing experience. She most recently served as the director of formulation and development at Groupe Rocher. Here, she led formulation and development across a team of 50 scientists for Yves Rocher, the best-selling botanical-based cosmetic brand in France.

Genel earned a double degree; a Master of Engineering from Ecole Centrale in Paris and a Master of Science in Pharmaceutical Engineering from Columbia University in New York City.

About Silk Therapeutics
Headquartered in Medford, MA, Silk Therapeutics, Inc. is the leader in silk protein solutions for human health and wellness. The founders are world-renowned pioneers in silk science and in silk-based applications that improve human health. Dr. Greg Altman, CEO, and Dr. Rebecca (Horan) Lacouture, Chief Operating Officer, have studied silk protein science for more than 17 years. Their scientific accomplishments resulted in the commercialization of the first FDA-cleared silk-based medical device for soft tissue repair in 2008. They are currently focused on redefining healthcare through the lens of how we treat skin, with a focus on reducing chemical exposure through common consumer products. Dr. Lacouture's personal experience as a cancer survivor, and the company's commitment to the wellbeing of its customers, is the foundation for Silk Therapeutics' line of clean, mission-driven skincare. For more information about our skincare and charitable mission, please visit www.silktherapeutics.com. 

Media Contact
Christina Teves
Silk Therapeutics
[email protected]

SOURCE Silk Therapeutics